A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy.
Journal Information
Full Title: Investig Clin Urol
Abbreviation: Investig Clin Urol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICTS OF INTEREST: SEY and SYK are employees of Janssen Korea Ltd. SEY was involved in study design, interpretation, funding, administrative support, and study supervision. SYK was involved in the statistical analysis and interpretation of the data. TWK declares participation in a Data Safety Monitoring Board or Advisory Board at Janssen. The remaining authors have nothing to disclose."
Funding Disclosure
Evidence found in paper:
"FUNDING: This study was funded by Janssen Korea (protocol no. 212082PCR4023)."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025